(Albany, USA) DelveInsight’s “Malignant Pleural Mesothelioma Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Malignant Pleural Mesothelioma, historical and forecasted epidemiology as well as the Malignant Pleural Mesothelioma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Malignant Pleural Mesothelioma market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Malignant Pleural Mesothelioma market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Malignant Pleural Mesothelioma treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Malignant Pleural Mesothelioma market.

 

Request for a Free Sample Report @ Malignant Pleural Mesothelioma Market Forecast

 

Some facts of the Malignant Pleural Mesothelioma Market Report are:

• According to DelveInsight, Malignant Pleural Mesothelioma market size in the 7MM was approximately USD 280 million in 2021.
• Leading Malignant Pleural Mesothelioma companies working in the market are Amphera BV, Polaris Pharmaceuticals, Oncovir, Inc, Oncotelic Inc, Sellas Life Sciences Group, Momotaro-Gene, PharmaMar, AstraZeneca, Targovax, TCR2 Therapeutics, Hoffmann-La Roche, Novartis,  MolMed, Ys Therapeutics, Merck Sharp & Dohme Corp., Mateon Therapeutics, Kissei Pharmaceutical Co., Ltd., NovoCure Ltd, AGC Biologics S.p.A, Aduro Biotech, Inc, Bristol-Myers Squibb, Novotech (Australia) Pty Limited, Kyorin Pharmaceuticals, ACADIA Pharmaceuticals, and others.
• Key Malignant Pleural Mesothelioma Therapies expected to launch in the market are MesoPher, Pegargiminase, Galinpepimut-S (Vaccine), OT-101, MTG201 + nivolumab, ZEPZELCA (lurbinectedin), IMFINZI, ONCOS-102, TC-210, TECENTRIQ Plus AVASTIN, and others.
• On June 2023, Oncovir announced a study that will examine the safety and potential effectiveness of poly-ICLC directly injected into malignant pleural mesothelioma at the time of biopsy up to 21 days prior to the cancer being removed by the surgeon
• In May 2023, Mateon Therapeutics ( Oncotelic Inc. ) announced a study of OT-101, a TGF-b2 inhibitor in combination of pembrolizumab in patients with malignant pleural mesothelioma. Both efficacy assessment, and safety and tolerability of various dose of OT-101 in combination of pembrolizumab are evaluated.
• In December 2022, efficacy and safety data from the phase II/III DENIM trial in Mesothelioma were released by Amphera.

 

Malignant Pleural Mesothelioma Overview

Malignant pleural mesothelioma is an aggressive and rare cancer that primarily affects the lining of the lungs (pleura) and is most commonly caused by exposure to asbestos fibers. It is characterized by the development of malignant cells in the pleural cavity, leading to symptoms such as chest pain, persistent cough, shortness of breath, and weight loss. Diagnosis often involves imaging tests, biopsies, and histopathological examination. Treatment options may include surgery, chemotherapy, radiation therapy, and targeted therapies. Prognosis is generally poor, with a low overall survival rate, but advancements in research and personalized treatment approaches offer some hope for improved outcomes in select cases.

 

Learn more about Malignant Pleural Mesothelioma treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/malignant-pleural-mesothelioma-market

 

Malignant Pleural Mesothelioma Market

The Malignant Pleural Mesothelioma market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Malignant Pleural Mesothelioma market trends by analyzing the impact of current Malignant Pleural Mesothelioma therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Malignant Pleural Mesothelioma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Malignant Pleural Mesothelioma market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Malignant Pleural Mesothelioma market in 7MM is expected to witness a major change in the study period 2019-2032.

 

Malignant Pleural Mesothelioma Epidemiology 

The Malignant Pleural Mesothelioma epidemiology section provides insights into the historical and current Malignant Pleural Mesothelioma patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Malignant Pleural Mesothelioma market report also provides the diagnosed patient pool, trends, and assumptions. 

 

Explore more about Malignant Pleural Mesothelioma Epidemiology @ https://www.delveinsight.com/sample-request/malignant-pleural-mesothelioma-market

 

Malignant Pleural Mesothelioma Drugs Uptake

This section focuses on the uptake rate of the potential Malignant Pleural Mesothelioma drugs recently launched in the Malignant Pleural Mesothelioma market or expected to be launched in 2019-2032. The analysis covers the Malignant Pleural Mesothelioma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Malignant Pleural Mesothelioma Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Malignant Pleural Mesothelioma market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

 

Malignant Pleural Mesothelioma Pipeline Development Activities

The Malignant Pleural Mesothelioma report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Malignant Pleural Mesothelioma key players involved in developing targeted therapeutics.

Malignant Pleural Mesothelioma Pipeline Therapies and Key Companies

• TECENTRIQ Plus AVASTIN: Hoffmann-La Roche
• MesoPher: Amphera BV
• Galinpepimut-S (Vaccine): Sellas Life Sciences Group
• MTG201 + nivolumab: Momotaro-Gene
• Pegargiminase: Polaris Pharmaceuticals
• ZEPZELCA (lurbinectedin): PharmaMar
• IMFINZI: AstraZeneca
• ONCOS-102: Targovax
• TC-210: TCR2 Therapeutics

 

Request for a sample report to understand more about the Malignant Pleural Mesothelioma pipeline development activities @ https://www.delveinsight.com/sample-request/malignant-pleural-mesothelioma-market

 

Malignant Pleural Mesothelioma Therapeutics Assessment

Major key companies are working proactively in the Malignant Pleural Mesothelioma Therapeutics market to develop novel therapies which will drive the Malignant Pleural Mesothelioma treatment markets in the upcoming years are Amphera BV, Polaris Pharmaceuticals, Oncovir, Inc, Oncotelic Inc, Sellas Life Sciences Group, Momotaro-Gene, PharmaMar, AstraZeneca, Targovax, TCR2 Therapeutics, Hoffmann-La Roche, Novartis,  MolMed, Ys Therapeutics, Merck Sharp & Dohme Corp., Mateon Therapeutics, Kissei Pharmaceutical Co., Ltd., NovoCure Ltd, AGC Biologics S.p.A, Aduro Biotech, Inc, Bristol-Myers Squibb, Novotech (Australia) Pty Limited, Kyorin Pharmaceuticals, ACADIA Pharmaceuticals, and others.

 

Learn more about the emerging Malignant Pleural Mesothelioma therapies & key companies @ https://www.delveinsight.com/sample-request/malignant-pleural-mesothelioma-market

 

Malignant Pleural Mesothelioma Report Key Insights

1. Malignant Pleural Mesothelioma Patient Population

2. Malignant Pleural Mesothelioma Market Size and Trends

3. Key Cross Competition in the Malignant Pleural Mesothelioma Market

4. Malignant Pleural Mesothelioma Market Dynamics (Key Drivers and Barriers)

5. Malignant Pleural Mesothelioma Market Opportunities

6. Malignant Pleural Mesothelioma Therapeutic Approaches

7. Malignant Pleural Mesothelioma Pipeline Analysis

8. Malignant Pleural Mesothelioma Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Malignant Pleural Mesothelioma Market

 

Table of Contents

1. Key Insights

2. Executive Summary

3. Malignant Pleural Mesothelioma Competitive Intelligence Analysis

4. Malignant Pleural Mesothelioma Market Overview at a Glance

5. Malignant Pleural Mesothelioma Disease Background and Overview

6. Malignant Pleural Mesothelioma Patient Journey

7. Malignant Pleural Mesothelioma Epidemiology and Patient Population

8. Malignant Pleural Mesothelioma Treatment Algorithm, Current Treatment, and Medical Practices

9. Malignant Pleural Mesothelioma Unmet Needs

10. Key Endpoints of Malignant Pleural Mesothelioma Treatment

11. Malignant Pleural Mesothelioma Marketed Products

12. Malignant Pleural Mesothelioma Emerging Therapies

13. Malignant Pleural Mesothelioma Seven Major Market Analysis

14. Attribute Analysis

15. Malignant Pleural Mesothelioma Market Outlook (7 major markets)

16. Malignant Pleural Mesothelioma Access and Reimbursement Overview

17. KOL Views on the Malignant Pleural Mesothelioma Market

18. Malignant Pleural Mesothelioma Market Drivers

19. Malignant Pleural Mesothelioma Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting